A Phase 2 interventional study of Abaloparatide in Lumbar Degenerative Disease, sponsored by State University of New York at Buffalo. Enrolling by invitation at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by State University of New York at Buffalo · Phase 2, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 481 studies in Osteoporosis with a site in United States — 26 open to participants now, 36 under way, none of them phase 3. Osteoporosis · United States.
Among the 481 studies in Osteoporosis with a site in United States, this one is the 211th largest by planned enrollment of the 374 interventional ones that give a count, is one of 8 that started in 2026, is one of 73 in phase 2, reaches primary completion later than 24 of the 34 other live ones, and was the 478th registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →26 of the 481 studies in Osteoporosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Amber Implants B.V. · Sites in United States
Ages 21–85
University of Connecticut · Sites in United States
Ages 45–70 · Women only · Healthy volunteers
Precision IO Group · Sites in United States
Ages 22+
AO Foundation, AO Spine · Sites in United States, Argentina, Brazil and 11 more countries
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
481 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 93 · Phase 3 78 · Phase 4 61
First in 1985; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 73 across the 374 interventional studies, 100 across the 97 observational. Of the 405 that completed or were terminated, 154 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
112 of 481 have an industry lead sponsor. The 10 most frequent:
State University of New York at Buffalo is the lead sponsor of 294 studies on the registry; 63 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
State University of New York at Buffalo has 1 study filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
14 of the studies in Osteoporosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06577935Angitia BiopharmaceuticalsA Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | 2026-12 |
| NCT07325578Precision IO GroupU.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures | 2027-01 |
| NCT05151484Madhumathi RaoNovel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover | 2027-01-31 |
| NCT07154719Pennington Biomedical Research CenterGLP-1R Actions on Muscle and the Skeleton | 2027-02-01 |
| NCT05775094Memorial Sloan Kettering Cancer CenterA Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | 2027-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 481 studies in Osteoporosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine the change in VBQ score, T score, TBS, and Hounsfield Units (HU) after 3-6 months of treatment with abaloparatide in osteoporotic patients who will undergo spinal fusion and decompression for lumbar degenerative disease. The main question[s] it aims to answer is:
Does abaloparatide improve bone density in these patients, as defined by VBQ score compared to traditional methods such as DEXA and Hounsfield Units Does abaloparatide reduce the incidence of postoperative mechanical complications, including adjacent segment disease, subsidence, and proximal junctional kyphosis (PKJ)?
Participants will undergo a presurgical assessments and trained in clinic on the subcutaneous application of abaloparatide. Prior to treatment, patients will have baseline assessments, including a lumbar MRI, DEXA scan, and lumbar CT. Post-surgically, participants will administer abaloparatide and return to clinic after 3-6 months for follow-up assessments including a new MRI, lumbar CT, and DEXA scan. Patients will be followed for up to 2 years postoperatively to identify complications such as adjacent segment disease, pseudarthrosis, failure of instrumentation, and PJK.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of Osteoporosis based on the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3-6 months of self-administered abaloparatide in osteoporotic patients will undergo spinal fusion and decompression for lumbar degenerative disease
Drug: Abaloparatide
3-6 months of treatment with abaloparatide in osteoporotic patients who will undergo spinal fusion and decompression for lumbar degenerative disease
Improvement in Bone Quality
Improvement in bone quality, using Vertebral Bone Quality
Time frame: 6 weeks post-op
Improvement in Bone Quality
Improvement in bone quality, using Hounsfield Units
Time frame: 6 weeks post-op
Improvement in Bone Quality
Improvement in bone quality, using DEXA (Dual-Energy X-ray ABsorptiometry)
Time frame: 6 weeks post-op
Improvement in Bone Quality
Improvement in bone quality, using Vertebral Bone Quality
Time frame: 6 months post-op
Improvement in Bone Quality
Improvement in bone quality, using Hounsfield Units
Time frame: 6 months post-op
Improvement in Bone Quality
Improvement in bone quality, using DEXA (Dual-Energy X-ray ABsorptiometry)
Time frame: 6 months post-op
Improvement in Bone Quality
Improvement in bone quality, using Vertebral Bone Quality
Time frame: 12 months post-op
Improvement in Bone Quality
Improvement in bone quality, using Hounsfield Units
Time frame: 12 months post-op
Improvement in Bone Quality
Improvement in bone quality, using DEXA (Dual-Energy X-ray ABsorptiometry)
Time frame: 12 months post-op
Improvement in Bone Quality
Improvement in bone quality, using Vertebral Bone Quality
Time frame: 24 months post-op
Improvement in Bone Quality
Improvement in bone quality, using Hounsfield Units
Time frame: 24 months post-op
Improvement in Bone Quality
Improvement in bone quality, using DEXA (Dual-Energy X-ray ABsorptiometry)
Time frame: 24 months post-op
Surgical Complications
Presence of complications associated with fusion, such as Proximal Junctional Kyphosis (PJK), proximal junctional failure (PJF), pseudoarthrosis, subsidence, adjacent segment disease, mechanical failure, reoperation, and patient-reported outcomes.
Time frame: 6 weeks post-operatively
Surgical Complications
Presence of complications associated with fusion, such as PJK, PJF, pseudoarthrosis, subsidence, adjacent segment disease, mechanical failure, reoperation, and patient-reported outcomes.
Time frame: 6 months post-operatively
Surgical Complications
Presence of complications associated with fusion, such as PJK, PJF, pseudoarthrosis, subsidence, adjacent segment disease, mechanical failure, reoperation, and patient-reported outcomes.
Time frame: 12 months post-operatively
Surgical Complications
Presence of complications associated with fusion, such as PJK, PJF, pseudoarthrosis, subsidence, adjacent segment disease, mechanical failure, reoperation, and patient-reported outcomes.
Time frame: 24 months post-operatively
Plan to share: No — No individual participant data will be shared with other researchers. At the close of the study, statistical data may be shared but it will all be aggregated with outliers removed.
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 23 months after the start.
Of 33 non-industry phase 2 interventional studies under Osteoporosis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 65. This study's planned 23 months is below that.
Counting every sponsor, half of 42 studies reached it within 47 months; a quarter within 29 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abaloparatide
State University of New York at Buffalo →